Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Apr 29, 2025
Open Peer Review Period: Apr 30, 2025 - Jun 25, 2025
Date Accepted: Jul 29, 2025
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Costs and Cost Effectiveness of an Enhanced Web-Based Physical Activity Intervention for Latinas: 12- and 24-Month Findings from Pasos Hacia La Salud II
ABSTRACT
Background:
Increasing adherence to physical activity (PA) guidelines could prevent chronic disease morbidity and mortality, save considerable healthcare costs, and reduce health disparities. We previously established the efficacy and cost-effectiveness of a web-based PA intervention for Latina women, which increased PA but few participants met PA guidelines and long-term maintenance was not examined. A new version with enhanced intervention features was found to outperform the original intervention in long-term guideline adherence.
Objective:
to determine the costs and cost-effectiveness of the enhanced multi-technology PA intervention vs. the original web-based intervention in increasing minutes of activity and adherence to guidelines
Methods:
Latina adults (N=195) were randomly assigned to receive a Spanish language individually tailored web-based PA intervention (Original), or the same intervention additional phone calls and interactive text messaging (Enhanced). PA was measured at baseline, 12 months (end of active intervention), and 24 months (end of tapered maintenance) using self-report (7-Day Physical Activity Recall Interview) and ActiGraph accelerometers. Costs were estimated from a payer perspective and included all features needed to deliver the intervention, including staff, materials, and technology. Cost effectiveness was calculated as the cost per additional minute of PA added over the intervention, and the incremental cost effectiveness ratios of each additional person meeting guidelines.
Results:
at 12 months, the costs of delivering the interventions were $16/person/month and $13/person/month in the Enhanced and Original arms, respectively. These costs fell to $14 and $8 at 24 months. At 12 months, each additional minute of self-reported activity in the Enhanced group cost $0.09 vs. $0.11 in Original ($0.19 vs. $0.16 for ActiGraph), with incremental costs of $0.05 per additional minute in Enhanced beyond Original. At the end of maintenance (24 months), costs per additional minute fell to $0.06 and $0.05 ($0.12 vs. $0.10 for ActiGraph), with incremental costs of $0.08 per additional minute in Enhanced ($0.20 for ActiGraph). Costs of meeting PA guidelines at 12 months were $705 vs. $503 in Enhanced vs. Original, and increased to $812 and $601 at 24 months. The ICER for meeting guidelines at 24 months was $1837 (95% CI $730.89-$2673.89) per additional person in the Enhanced vs. Original arm.
Conclusions:
As expected, the Enhanced intervention was more expensive, but yielded better long-term maintenance of activity. Both conditions were low costs relative to other medical interventions. The Enhanced intervention may be preferable in high risk populations, where more investment in meeting guidelines could yield more cost savings. Clinical Trial: NCT03491592
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.